Biotech "Tweets of the Week"
Data Deluge
(October 16-21, 2016)
Headlines - $ALKS $CELG $CERC $CRSP $KITE $SRPT $PBYI $PTCT
In the News - $ACAD $ALNY $ARIA $CRBP $DEPO $GILD $MDCO $PFE $PRQR $RIGL $SGMO $XBI $IBB
Looking for past biotech highlights? Check out the Biotech Tweets of the Week archive.
Celgene's long-awaited Crohn's disease data leaves questions $CELG
$CELG designed the GED-0301 endoscopy study to be pretty much impossible to usefully interpret, and the study was a success.
— Year of Glad (@pemulisking) October 16, 2016
@tgtxdough @MauriceOnTW @BioDueDiligence Not if one is similar to placebo.
— JQ (@jq1234t) October 17, 2016
$CELG Cohn's Pill Data Unspectacular but Perhaps Good Enough https://t.co/0FNApV03GC
— Adam Feuerstein (@adamfeuerstein) October 17, 2016
back in sept, $CELG wouldn't provide detail about '301dose-response, noting 'need to preserve data for later use'...or cos there wasn't one?
— zach (@zbiotech) October 17, 2016
ehhhh...15%?$CELG pic.twitter.com/sMyum0wucM
— zach (@zbiotech) October 18, 2016
$CELG GED-0301 only 15% responder rate for >50% cutoff, i.e. probably worse than placebo in $GLPG filgotinib trialhttps://t.co/8E9Jpg1CxX pic.twitter.com/4B9GSZogu5
— Andy Biotech (@AndyBiotech) October 18, 2016
@adamfeuerstein @zbiotech Everyone uses cross trial comparisons if it confirms their beliefs not just sell side
— David Sobek (@dsobek) October 17, 2016
PTC hit with setback in attempt to ride Sarepta's coattails $PTCT $SRPT
$PTCT FDA denied the appeal to refile #DMD drug Translarna https://t.co/VsGBmkfJ8a
— Joe (@GantosJ) October 17, 2016
FDA to $PTCT: stop wasting our time.
— Brad Loncar (@bradloncar) October 17, 2016
$PTCT Not great news from US and EU fronts. "major objections" from EMA
— j l (@bio_clouseau) October 17, 2016
So why isn't the FDA worried about PTC's market cap?
— Charley Grant (@CGrantWSJ) October 17, 2016
FDA denies $PTCT appeal of Translarna RTF letter --> need to step up their advocacy game
— Lisa LaMotta (@BioWriterChik) October 17, 2016
$PTCT how many more deaths can ataluren still die?
— Dirk Haussecker (@RNAiAnalyst) October 18, 2016
$ptct down 50% in 4 days
— sb (@smallcapbiotech) October 20, 2016
Kite Pharma lays out its vision for the future at R&D Day $KITE
Big theme here: First mover$KITE
— John Carroll (@JohnCendpts) October 18, 2016
I'm looking through the $KITE slide deck, and the last slide still guides for the BLA submission in 2016. ZUMA-1 primary data 1Q2017.
— Brad Loncar (@bradloncar) October 18, 2016
Point of the on/off switch on $KITE BCMA CAR (KTE-585) is to avoid need for rescue bone marrow transplant, says Margo Roberts
— Jacob Plieth (@JacobPlieth) October 18, 2016
@CarolineYLChen The liquidation auction will be all that more exciting.
— Adam Feuerstein (@adamfeuerstein) October 18, 2016
$KITE says their average cell processing time is 7 days. Claims its fastest in the industry.
— Brad Loncar (@bradloncar) October 18, 2016
$KITE peak sales opportunity in ASCT eligible patients 12-months after launch ~$450M and 2,250 patients
— Dr. Paul DeSantis (@DrPaulyDeSantis) October 18, 2016
Talked to $KITE. To clarify: pre-BLA mtg within a month. FDA could delay/ask for rolling submission. Arie's pt is co is ready to file now.
— Caroline Chen (@CarolineYLChen) October 18, 2016
FDA and EMA regulators make waves on rare diseases, transparency $SRPT
Eteplirsen approval controversy rages on. FDA's J Jenkins just spent 20 mins savaging Sarepta's data and process. #NordSummit #Duchenne
— Alicia Ault (@aliciaault) October 18, 2016
Eteplirsen "lesson learned" from @US_FDA's Jenkins: personal attacks will make it challenging to recruit and retain reviewers #NORDSummit
— Kate Rawson Powell (@Kate_Rawson) October 18, 2016
#FDA Woodcock on $SRPT #eteplirsen approval: It was a judgment call & I made the judgment the standard was met #NORDSummit #pharma #biotech
— Donna Young (@DonnaYoungDC) October 18, 2016
FDA official: ``Sarepta NOT a good model for other development programs'' $SRPT
— Doni Bloomfield (@DoniBloomfield) October 19, 2016
``https://t.co/h7f91UcLFS
Hoping the FDA hurries up and rejects something soon so I can stop reading tweets about how everything's a go in the post-Sarepta world
— Year of Glad (@pemulisking) October 20, 2016
Definitely one to bookmark: The new EMA database for clinical trial info: https://t.co/pxZUwzvbvO
— Zach Brennan (@ZacharyBrennan) October 20, 2016
Impressive factoid, 2 of 260,000 pages of clinical data redacted by EMA. That transparency would go over great here https://t.co/kYq28e9du1
— Andrew G. (@BioDueDiligence) October 21, 2016
$CRSP IPO completes the "CRISPR trifecta" $EDIT $NTLA
Can CRISPR Save Ben Dupree? https://t.co/eCtja7LTxl
— Antonio Regalado (@antonioregalado) October 17, 2016
CRISPR Therapeutics priced a downsized 4 million shares at a below range $14.00 and will debut Wednesday. $CRSP
— IPO Boutique (@IPOBoutique) October 18, 2016
CRISPR trifecta completed. https://t.co/f1GyBD7fp0
— Michael Gilman (@michael_gilman) October 19, 2016
Patients treated: zero point zero. $NTLA, $EDIT (and now $CRSP) have been monster shorts. https://t.co/J3k5fS9qfN
— Biotech, Beats & BBQ (@BiotechBbqBeats) October 19, 2016
@pemulisking @BiotechBbqBeats short CRISPR, long CRISPR litigators
— Jake King (@FajaJake) October 19, 2016
Bioterror? J Lo to star in "C.R.I.S.P.R." a procedural thriller on NBC . https://t.co/78N9XTC0ao
— Antonio Regalado (@antonioregalado) October 19, 2016
Puma "leads" latest round of biotech fundraising $PBYI $SNSS $NKTR
$NKTR $175m offering
— Shane Blackmon (@shaneblackmon) October 17, 2016
1 for 6 reverse, followed up by secondary w/common and preferred a month later, well done $SNSS
— zach (@zbiotech) October 18, 2016
@odibro don't blame them. $13 to $20 - $7 jump < 7 weeks
— Raj R (@rajramaswamy) October 18, 2016
$CERU $20M ATM Stock Purchase Agreement with Aspire Capital Fund
— Bio Stocks™ (@BioStocks) October 19, 2016
$PBYI Desperate Money Grab Signals Breast Cancer Drug Trouble https://t.co/FU6V0QMDae Just 3 weeks ago, CEO said no dilutive financing...
— Adam Feuerstein (@adamfeuerstein) October 20, 2016
$NWBO $5m direct offering $.38/share
— Shane Blackmon (@shaneblackmon) October 21, 2016
Third time is the charm for Alkermes depression drug $ALKS $CERC
Alkermes depression drug finds success on third study attempt $ALKS https://t.co/BOnNZKQhcC via @TheStreet
— Adam Feuerstein (@adamfeuerstein) October 20, 2016
@bio_clouseau nothing on effect size in the PR
— Terry Smith (@TerryMSmith) October 20, 2016
Big move for Alkermes, but the stock was at $79 when the year got started... #justsaying
— Charley Grant (@CGrantWSJ) October 20, 2016
$ALKS adds $3B
— Jake King (@FajaJake) October 20, 2016
$CERC..$4.95 this one is going to explode tomorrow IMO. Small float & good news from $ALKS news. Agree w/ @AF_biotech here. 29m MC here. https://t.co/3q2nF0huOI
— Sheff (@SheffStation) October 20, 2016
not a joke: the hold music on the $ALKS call is "Don't Stop Believing" https://t.co/HMdlJbdQCN
— Damian Garde (@damiangarde) October 20, 2016
$ALKS +43%$CERC +56%
— Schulz (@portefeuillefun) October 21, 2016
at the end of extended trading.
Cerecor’s $1M Lilly deal put it in the right place at the right time today$CERC up 34%https://t.co/NcjMDAl5uT
— John Carroll (@JohnCendpts) October 21, 2016
As seen on the stream
"...hospitals charge almost six times more, on average, than they pay for medicines.” https://t.co/Ae5zF76hUI
— Dan Smithey (@dan_smithey) October 16, 2016
Looks like Califf's tenure as FDA Commissioner will be rather short...https://t.co/DPXMIFBV5o pic.twitter.com/Nf1G4mDDaO
— Andy Biotech (@AndyBiotech) October 17, 2016
Profiled 4 v interesting early-stage women’s health companies @evemedical @sandstonedx @millendotx @bludiagnostics https://t.co/rFtE2dpwgU
— David Sable (@dbsable) October 16, 2016
Scoop: Ex-Celgene Dealmaker Tom Daniel Charts a New Course Advising Biotechs https://t.co/uq2iMZdVX3 $CELG
— Ben Fidler (@BentheFidler) October 17, 2016
$REGN $TEVA Anti-NGF fasinumab on clinical hold again due to a case of adjudicated arthropathy
— Andy Biotech (@AndyBiotech) October 17, 2016
@JohnCendpts Re biotech bear mrkt start, $XBI $IBB peaks were 7/20/15.Already down 10% on 9/21/15 day of Clinton tweet
— j l (@bio_clouseau) October 17, 2016
Interesting review looking at antidepressant drugs' antimicrobial effects & relation to their efficacy for MDD https://t.co/qUwB2bKHaH
— Daphne Zohar (@daphnezohar) October 17, 2016
Today the White House and a slew of drug companies announce a big push for liquid biopsy as part of Moonshot. https://t.co/33WFxCXah9
— Matthew Herper (@matthewherper) October 17, 2016
Taking my girls to the fair, and then later I get to help dissect a CF lung today. Someone gets new lungs and we get new tissue to study!
— Michael Torres, PhD (@Mykalt45) October 17, 2016
Select European biotechs in one picture. pic.twitter.com/UymBuFgeVv
— vlad33301 (@vlad33301) October 17, 2016
@srqstockpicker $qure 6s in what is our worst stock pick ever by a wide margin. #noposition
— Adam Singer (@AdamSinger) October 17, 2016
Valeant will release earnings on the election day
— Drew Armstrong (@ArmstrongDrew) October 17, 2016
Mylan will release earnings the day after the election
(h/t to co-editor Cecile Daurat)
RBC says to buy any weakness on $BIIB EPS print...cos, alzheimer's
— zach (@zbiotech) October 17, 2016
Depomed and Starboard Announce Settlement Agreement $DEPO
— BioResearch (@BioResearchFund) October 17, 2016
$PFE Announces The U.S. Availability Of Biosimilar INFLECTRA https://t.co/4PPDUmSTZs
— Odi (@odibro) October 17, 2016
@srqstockpicker Some irony there if $BMG buys $EXEL for the drug indication they returned to $EXEL
— mark hennings (@marko1332) October 17, 2016
@SheffStation I've incurred enough pain in pain stocks (acute & chronic) to know to stay away. But what IS interesting is medicinal MJ.
— Adam Singer (@AdamSinger) October 17, 2016
Biotech stock movers 10/17: $CRBP $CTRV $EGLT $NKTR $OHRP $PTCT $SPHS $XENT
— BioPharmCatalyst (@crusadernz) October 17, 2016
BPC Pipeline updates: $OMER $RTTRhttps://t.co/THW6leJdOU
It's funny how we are so quiet on twtr these days with consecutive down days in ibb and xbi. However, Lots of upcoming catalysts
— Pharm. D (@Pharmdca) October 18, 2016
@DrPaulyDeSantis Some stocks are stating to look attractive. The problem is they'll probably look even more attractive tomorrow.
— Joe (@Drchik23) October 18, 2016
#ESGCT16 Abstracts https://t.co/nhMYfk8YVt$AVXS $ADVM $BLUE $DMTX $GSK $SHPG $QURE $RGNX $MDGN $NTLA $EDIT $BIIB $IONS $BMRN $SGMO $ONCE
— Zack (@BioTerp) October 18, 2016
FDA hands out $23M for rare disease development: https://t.co/idOQEjudxY
— FierceBiotech (@FierceBiotech) October 18, 2016
FDA accepts resubmitted filing for AstraZeneca's hyperkalaemia therapy ZS-9 https://t.co/uI9WdHsN3T pic.twitter.com/cdQFteD7XK
— Biotechnology (@BiotechnologyRR) October 18, 2016
— Sudhanva Raj (@SudhanvaRaj) October 18, 2016
Zytiga a 2 billion a dollar year drug (HT @bradloncar ). Sales appear to have flattened until a new indication rolls around pic.twitter.com/83HV47oIQB
— daviesbj (@daviesbj) October 18, 2016
couldn't sleep so did an early morning literature crawl
— Paul D. Rennert (@PDRennert) October 18, 2016
check the feed if interested#immunotherapy #morecoffee
$ADAP Announces Initiation of Triple Tumor Study to Evaluate its SPEAR® T-Cell Therapy Targeting MAGE-A10 https://t.co/lVZakOwAlp
— Odi (@odibro) October 18, 2016
In light of the recently announced easing of taxes on stocks, I'm happily adding $FAGR.EBR on my watchlist. #biotech
— Kevin Jacobs (@krljacob) October 18, 2016
$STJ
— Tom Wrigley (@WrigleyTom) October 18, 2016
St. Jude Medical, FDA And Top Pediatric Cardiology Experts Announce New Clinical Trial To Treat Congenital Heart Defects -Dow Jones
Added 150 $BLUE at 56.06 for total 500 #zzporte shares cost basis 84.12 @portefeuillefun
— Tony Friedman (@zzlangerhans) October 18, 2016
$JNJ warns Prop 61 will create "access barriers" to patients if it passes.
— Charley Grant (@CGrantWSJ) October 18, 2016
$KERX seems pretty beat up. I am long. PDUFA 11/13. Presentation same week. https://t.co/YMCprNWjLd
— DeadCatBill (@getbillasap) October 18, 2016
$alny nice move from low 34's, $cemp adcom coming (big catalyst)
— Pharm. D (@Pharmdca) October 18, 2016
What do #biotech CEOs have to say about the markets, pricing, the election and more? Our survey results #FDA #VC https://t.co/kO3lXxVvHd…
— Shehla Shakoor (@ShehlaShakoor) October 18, 2016
Access to capital for #biotech?https://t.co/csxjjUVRFc pic.twitter.com/Aw59nOE6as
— John Carroll (@JohnCendpts) October 18, 2016
Price transparency in medicine would completely transform health care - and we're not ready for that as a society in the U.S. #AdvaMed16
— Michelle Fay Cortez (@FayCortez) October 18, 2016
calls up ~100%, probably smart to sell half here though thesis unchanged. Biggest upside from combo of +data AND +Repatha CVOT
— I.M.Opinion (@subset_member) October 18, 2016
$TRIL short interest down 10% in last week; wise move, but plenty short fuel still left for this micro float w/ only 6 weeks to #ASH16
— whutrades (@whutrades) October 18, 2016
I appreciate intent behind cancer moonshots, but feels hollow when you know someone facing impossible decisions due to lack of good drugs.
— Lisa Jarvis (@lisamjarvis) October 18, 2016
Interesting combination product for the treatment of Acute Suicidal Ideation in Bipolar Depression >> https://t.co/Z6GUwuSQu5 #NeuroRx
— BioNap (@JNapodano) October 18, 2016
Volume spike for Galapagos on Nasdaq trading. $GLPG
— BioStockAddict (@BioStockAddict) October 18, 2016
$ABEO wow .. so orphan drug designation and its up a whopping 16% crazy!!
— avidresearch (@avidresearch) October 18, 2016
$DVAX sent invitations to investors for a cancer R&D meeting on Dec. 9 — six days before the Heplisav Hep B vaccine PDUFA date.
— Adam Feuerstein (@adamfeuerstein) October 18, 2016
1st & only anti PDL1 cancer immunotherapy approved by the FDA for NSCLC
— Bursatil Biotech (@BursatilBiotech) October 18, 2016
Congrats @genentech !
With three anti-PD-1/L1 antibodies now approved in 2L NSCLC, two w/o PD-L1 assay, going to be interesting to see which oncologists choose
— Sally Church (@MaverickNY) October 18, 2016
First to market isn't always best... physicians & patients having more choices is a good thing here as there may be different plan coverage https://t.co/34jzGCvY7g
— Sally Church (@MaverickNY) October 18, 2016
#FDA Woodcock: Lots of rewards in working for FDA, but financial rewards are not among them#NORDSummit #pharma #biotech
— Donna Young (@DonnaYoungDC) October 18, 2016
$SGMO EVP of R&D resigning https://t.co/pGX6IzzYMF
— Vk (@biotechinvstr) October 18, 2016
$GWPH UK listing cancellation is quite unusual https://t.co/EQfi29zeJU Looks like Nasdaq ADRs will link to non-publicly traded security
— Jacob Plieth (@JacobPlieth) October 19, 2016
@tgtxdough funny how 'strong' translates to only 10% jump. Guess need super duper strong to notch 50% just to break even ?
— Raj R (@rajramaswamy) October 19, 2016
$MRNS Ganaxolone Ph1 Data Supports Progressing to Phase 2 in Patients with Status Epilepticus https://t.co/qMjB8ZeHWM
— Odi (@odibro) October 19, 2016
Despite Promising Early Data, The New Cholesterol Lowering Drug - PCSK9si - Has Significant Hurdleshttps://t.co/g18vBsLg7H
— John LaMattina (@John_LaMattina) October 19, 2016
$MNTA CMO resigning
— Biotech Supernova (@biotechnova) October 19, 2016
$PBYI is still a $1.5B MC company, with a product no one wants, needs (or can tolerate). Still a long way to go down for this short.
— Biotech, Beats & BBQ (@BiotechBbqBeats) October 19, 2016
We are less than 3 wks away from discovering who will partner $HALO in I/O - @Roche for Atezo & $BMY for Opdivo- 2 popular possibilities
— fezziwig2008 (@fezziwig2008) October 19, 2016
Like an "In & Out" burger that is the way these stocks are being treated lately. People are locking short-term gains on any biotech stock!
— Sheff (@SheffStation) October 19, 2016
Exclusive: Perlara, the start-up founded by @eperlste, signs rare disease pact with Novartis https://t.co/fPNkZfEJpD by @lisamjarvis pic.twitter.com/JKkhHUUKjC
— C&EN (@cenmag) October 19, 2016
@23aloha @wrigleytom The biotech fade and fade is working well too, unfortunately
— Stan D'Andrea (@stanleydandrea) October 19, 2016
Drum roll, please, @MaxNisen & @CT_Morrison. Inflectra $946 vs. $1113 Remicade (WAC, 100mg IV powder for solution) TY, @TruvenHealth! pic.twitter.com/YLHNmVGrmo
— Scott Hensley (@scotthensley) October 19, 2016
$PRQR just a week from first human POC CF oral presentation data and with no runup/expectations, a striking R/R on upside potential
— Joel Thomson (@JSTBiotech) October 19, 2016
$SCYX MC is 53% cheaper than $CDTX but SCY-078 has better market potential than CD101
— Raj R (@rajramaswamy) October 18, 2016
FDA AdComm VOTE: Is there sufficient evidence 2 conclude that at least 1 of the #desmopressin doses is effective?
— SAC Tracker (@FDAadcomm) October 19, 2016
17-Y
1-N
Serenity/ $AGN
Very tough #bio environment right now. Bad names destroyed so shorting may not be worth it. Good names still getting clobbered. Can't win.
— Joe (@Drchik23) October 19, 2016
— 4th Quarter Capital (@4thQuarterCap) October 19, 2016
CAR-T and Gene Therapy applications will most likely go to this new FDA OTAT$JUNO $KITE $BLCM $BLUE $ONCE $QURE https://t.co/E3MEZBtjol
— Andy Biotech (@AndyBiotech) October 19, 2016
I am stating the obvious
— BioBounce.com (@BioBounce) October 19, 2016
I am off and running with a small position in $SCYX. 4-5 year investment.
— John Hall (@johnhallnj) October 19, 2016
Typical microcap risk of dilution but buying after POC.
Bumped into the excellent @MichelleNMeyer @MishaAngrist and @DShaywitz at #ASHG16. Glad I came
— Luke Timmerman (@ldtimmerman) October 19, 2016
$AFMD looked good in green today
— S Manian (@DrSManian) October 19, 2016
Sangamo CEO Sandy Macrae says gene therapy patients should be followed for life. Can companies afford that? Can they afford not to? #BIF16
— BioWorld Today (@BioWorld) October 19, 2016
@tgtxdough YTD change of big bios $IBB pic.twitter.com/KYorUxdONT
— dough (@tgtxdough) October 20, 2016
Glad futures green&hoping this last debate will inject some stability/certainty into the markets... Bio portfolio could definitely use that.
— Jason (@JasonHolman5) October 20, 2016
$RIGL 2nd Ph3 did not reach statistical significance (p=0.152) and the study did not meet its primary endpoint.https://t.co/1qR0wehJtL
— Andy Biotech (@AndyBiotech) October 20, 2016
@JohnCendpts You know your drug is weak when... a single placebo responder kills your study.
— Adam Feuerstein (@adamfeuerstein) October 20, 2016
They teach that at biotech CEO school.
$RIGL I love PM $1.95 buy $2.50 sell in about 5 minutes. Fun stuff
— The Flash (@Flashtrading) October 20, 2016
Congrats! @daphnezohar @PureTechH @odibro
— Juan P. Serrate, DVM (@JPZaragoza1) October 20, 2016
$RHHBY: Roche Revenue Gains as Sales of Breast Cancer Drugs Soar - Bloomberg #NotPursuing #MegaDeals https://t.co/egHRehSSD7?
— Helen Ong (@Lin_ling_88) October 20, 2016
What is "later this month"? It is already later this month $DPRX
— Julia Skripka-Serry (@JuliaSkripkaSer) October 20, 2016
appear to be a decent amount of debt financing deals from SMID Bios lately. Do they think equity valuations are currently low? Or rates?
— happyycamperr (@happyycamperr) October 20, 2016
Rewarding to get to share how we plan to give CF patients with nonsense mutations a fighting chance. Poster 56 at #NACFC2016. pic.twitter.com/tk3toqEmer
— Michael Torres, PhD (@Mykalt45) October 20, 2016
$GILD to submit Regulatory Applications for SOF/VEL/VOX in U.S. in Q4, Shortly Thereafter in EU.
— Bio Stocks™ (@BioStocks) October 20, 2016
#AASLD2016 #LiverMtg16 Late-breakers outhttps://t.co/XOPYU9o6oP$TBRA $AGN Ph2b CENTAUR$GILD ASK1 inh in #NASH$CBAY MBX-8025 in PBC
— Andy Biotech (@AndyBiotech) October 20, 2016
Strange biotech action today... $IDRA is one. $1.65 to 2.02 and back down
— Shane Blackmon (@shaneblackmon) October 20, 2016
More great reporting from the @WSJ on Theranos: the human implications https://t.co/6hMdSFz9pM
— Meg Tirrell (@megtirrell) October 20, 2016
AARP's Purvis: Medical advances like biologics are meaningless if no one can afford to use them. #pharma #biosimilars
— Sarah Karlin-Smith (@SarahKarlin) October 20, 2016
$OMER how many PRs in the last 2 weeks?
— avidresearch (@avidresearch) October 20, 2016
Using music to map out protein structure: File this in the "Why would they ever think of this?? But cool." category https://t.co/XMSZiAPLjl
— Meghana Keshavan (@megkesh) October 20, 2016
1st 2 hrs- 25,500 $ZIOP calls mostly @ ask + 1500 Jan 5 puts sold to open bullish. Cooper intends to dominate solid tumors. $KITE $XON $JUNO
— rc (@pharmamaven) October 20, 2016
Musings on $GILD POLARIS studies of SOF/VEL/VOX 3-DAA regimen:https://t.co/0cC5Js57Cn
— Roy Friedman (@DewDiligence) October 20, 2016
Nice volume so far in $mdgn more than daily avg...tomorrow it starts to trade on NASDAQ
— VM (@VM1409) October 20, 2016
Sen Bernie Sanders, Rep Elijah Cummings send letter to $ARIA requesting information on pricing of Iclusig: https://t.co/wh0Tdi8Yxt
— Meg Tirrell (@megtirrell) October 20, 2016
$ARIA investors flipped to republican
— Boaty McBoatface (@srqstockpicker) October 20, 2016
Very relevant for $SAGE $MRNS I'll comment later
— CNS Investing (@CNS_Investing) October 20, 2016
Misleading diagnosis was found in 40% of European patients (n=12k) due to fail dna sequencing.
— Bursatil Biotech (@BursatilBiotech) October 20, 2016
Be aware of this pic.twitter.com/yb9jFA96Na
$ZIOP BOOM BOOM
— biotech 2050 (@Biotech2050) October 20, 2016
$MRK KEYNOTE-045 Studying KEYTRUDA (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early
— Bio Stocks™ (@BioStocks) October 21, 2016
Biotech outflows return, per Raymond James: net outflows of $646m for wk ending Oct 19. YTD net outflows $7.7B
— Meg Tirrell (@megtirrell) October 21, 2016
— The Daytrade™ (@d4ytrad3) October 21, 2016
Biotech shouldn't be sweating the election quite so much. https://t.co/yQWu9ZGdZc
— Max Nisen (@MaxNisen) October 19, 2016